source
- PhRMA pushes back as prescription drug spending continues to rise, according to STAT+ newsletterSTAT+ Health Care Inc. newsletter author Bob Herman reports on the growing concern that prescription drug spending is rising despite industry attempts to downplay it. The piece appears in the July…
- FDA says Capricor's DMD cell therapy failed to meet Phase 3 endpointsThe FDA briefing documents released before an advisory committee meeting state that the Phase 3 trial of Capricor's deramiocel did not achieve its pre-specified primary and secondary efficacy endpo…